NEW YORK (GenomeWeb) – Enzo Biochem reported after the close of the market on Monday that its fiscal second quarter revenues fell 26 percent year over year, largely due to a 36 percent drop in its clinical services revenues.

For the three months ended Jan. 31, the diagnostics company said total revenues sank to $19.3 million from $26.2 million a year earlier.